MARKET WIREYahoo Finance Australia • 15h ago
REGENXBIO Inc. (RGNX) stock price, news, quote and historyYahoo Finance Australia report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
Why RGNX Stock dropped -2.83% Today — RQD Quant Desk Flash
$7.20 -2.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.15
REGENXBIO Inc. (RGNX) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $489.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RGNX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RGNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, REGENXBIO Inc. (NASDAQ: RGNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.20 (-2.83% 1D, market cap $489.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGNX ranks #924 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RGNX compare to SRZN and EDIT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RGNX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SRZN (Surrozen Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $524.4M) and EDIT (Editas Medicine Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M). Among the 5-stock peer group, RGNX leads on earnings multiple (N/A) while RGNX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RGNX?
▼
Per RGNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590877), REGENXBIO Inc. generated $170.4M in revenue (+104.5% YoY), -$193.9M in net income, and -$126.4M in free cash flow against $453.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.15 (-0.70%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RGNX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY RGNX SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (19% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$7.77-8% Next Q
35
Q2 (-2Q)Grade E$7.15-8% Next Q
32
Q3 (-1Q)Grade E$6.58+9.4% Next Q
30
CurrentGrade E$7.20-10.3% Hist 90D α
27
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a RGNX Turnaround Squeeze
While RGNX currently carries a cautious 27/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.92) and Max Pain ($7.56) forces dealer call-delta covering toward $17.00.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RGNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RGNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RGNX Stock dropped -2.83% Today — RQD Quant Desk Flash
REGENXBIO Inc. (RGNX) dropped -2.83% to $7.20, trading at 16% of its 52-week range ($5.45 – $16.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($5.45 – $16.19) with RSI-14 at 49.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live RGNX Headlines & Catalysts
CATALYSTInvesting.com • 18h ago
Mizuho initiates Regenxbio stock coverage with outperform ratingInvesting.com report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 21h ago
RegenXBio Announces Board Leadership Changes After ResignationThe Globe and Mail report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Full Transcript: Regenxbio Q2 2026 Earnings Call - Regenxbio (NASDAQ:RGNX)Benzinga report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene TherapyYahoo Finance report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside CallYahoo Finance report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
REGENXBIO stock: Bank of America sets USD 15.00 target for REGENXBIO stockad-hoc-news.de report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
CATALYSTad-hoc-news.de • 1d ago
REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percentad-hoc-news.de report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4d ago
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREYahoo • 4d ago
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational HighlightsREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 5, at 8:00 a.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and operational
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RGNX)
- ✓Walkthrough of RGNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RGNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.32%⚡ TESTING RESISTANCE
2026-11-02O $7.24H $7.41L $7.20C $7.20VOL 1.04M
RES: $7.45SUP: $6.34SMA50: $7.92SMA200: $9.14
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RGNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +104.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on RGNX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RGNX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RGNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RGNX)
Health Care Rank #924 of 1016
⚔️ SRZN vs RGNX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RGNX vs. SRZN, EDIT, PROK, VALN)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, REGENXBIO Inc. (RGNX) ranks #924 by composite RQD confidence (27/100, grade E) and #457 by equity capitalization ($489.2M). Within this direct 5-issuer industry benchmark cohort, RGNX leads on earnings valuation at N/A trailing P/E, while RGNX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RGNX at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RGNX
ACTIVE
REGENXBIO Inc. | E | 27/100 | — | — | -35.0% | -2.83% | $489.2M | Benchmark Subject |
| SRZN Surrozen Inc. | D- | 38/100 | — | — | -35.0% | -1.43% | $524.4M | /srzn-vs-rgnx → |
| EDIT Editas Medicine Inc. | D- | 38/100 | — | — | -35.0% | -8.87% | $450.0M | /edit-vs-rgnx → |
| PROK ProKidney Corp. (Class A) | D- | 37/100 | — | — | -35.0% | -11.90% | $444.4M | /prok-vs-rgnx → |
| VALN Valneva SE | D | 48/100 | — | — | — | -4.55% | $541.8M | /valn-vs-rgnx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590877In its most recent audited fiscal period (FY2025, filed 2025-12-31), REGENXBIO Inc. (RGNX) reported GAAP revenue of $170.4M (+104.5% vs. FY2024 revenue of $83.3M , and +88.9% cumulative change since FY2023) , GAAP net income of -$193.9M, operating cash flow of -$124.0M, and free cash flow of -$126.4M (+28.0% YoY). On the balance sheet, RGNX closed FY2025 with $453.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.4M | -$193.9M | -$124.0M | -$126.4M | $453.0M | — |
| FY2024 (FY) | 2024-12-31 | $83.3M | -$227.1M | -$173.1M | -$175.6M | $466.0M | — |
| FY2023 (FY) | 2023-12-31 | $90.2M | -$263.5M | -$218.4M | -$218.4M | — | — |
3. RGNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RGNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, REGENXBIO Inc. (NASDAQ: RGNX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.20 (-2.83% 1D, market cap $489.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RGNX ranks #924 in composite RQD confidence.
How does RGNX compare to SRZN and EDIT in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RGNX carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SRZN (Surrozen Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $524.4M) and EDIT (Editas Medicine Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $450.0M). Among the 5-stock peer group, RGNX leads on earnings multiple (N/A) while RGNX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RGNX?
Per RGNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590877), REGENXBIO Inc. generated $170.4M in revenue (+104.5% YoY), -$193.9M in net income, and -$126.4M in free cash flow against $453.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RGNX trading relative to its 50-day, 200-day, and 52-week technical levels?
RGNX last traded at $7.20 (-2.83% on volume of 1,061,651 shares), positioning the stock -9.09% below its 50-day simple moving average ($7.92) and -21.23% below its 200-day simple moving average ($9.14). Across its 52-week range of $5.45 to $16.19, RGNX sits at the 16.3% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.30 to $8.10).
RGNX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is RGNX stock moving today?
Why RGNX Stock dropped -2.83% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 27/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
RGNX — REGENXBIO Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, RGNX scores 27 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 4 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support the valuation.
- Whale / 13F Flow: 5 / 20. The RQD rating scores institutional accumulation and options positioning at 5 of 20. The source data does not provide the underlying 13F holdings, so the reasoning behind this score cannot be verified here.
- Insider Conviction: 5 / 20. The RQD rating scores SEC Form 4 and Congressional PTR cluster flow at 5 of 20. Insider and congressional transaction detail is not itemized in the source data.
- Macro Regime Fit: 5 / 20. Per the RQD rating, beta is 1.0 and the score reflects sector sensitivity. A prospective investor should note that the stock moves in line with the broader market, offering no defensive characteristic from the beta figure alone.
- Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 0.2, Piotroski F is 4/9, and Debt/Equity is 0.5. The low Altman Z is the most significant forensic warning in the rating.
Taken together, the rating points to a company with negative cash generation, weak institutional and insider conviction signals, and a stressed balance sheet. The upside case rests on future clinical or commercial outcomes that the source data does not quantify. The valuation tradeoff is that a $489.2M market cap sits against deeply negative operating and free cash flow, so the stock's price depends on events beyond the reported financials.
Business
Per the Roarable profile, REGENXBIO Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). The source data does not describe specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $170.4M for FY 2025, indicating it generates sales, but the source data does not break down the sources of that revenue.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $170.4M | $-161.2M | $-193.9M | N/A | $-126.4M | $34.5M | N/A |
| FY 2024 | $83.3M | $-233.3M | $-227.1M | N/A | $-175.6M | $57.5M | N/A |
| FY 2023 | $90.2M | $-268.1M | $-263.5M | N/A | $-218.4M | N/A | N/A |
Per the market data, operating margin and net margin are each -60%, and gross margin is 0%. ROIC is -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both weak readings. Cash declined from $57.5M in FY 2024 to $34.5M in FY 2025, and the source data reports Debt/Equity of 0.5 with debt values otherwise not available in source data.
Recent Catalysts & News Wire Analysis
- Mizuho initiation (GREEN, CATALYST): Per the Investing.com item, Mizuho initiated coverage with an outperform rating, the only positive-signal item in the feed.
- Board leadership changes (YELLOW, MARKET WIRE): Per The Globe and Mail item, the company announced board leadership changes following a resignation.
- Q2 2026 earnings call transcript (YELLOW, MARKET WIRE): Per Benzinga, a transcript of the Q2 2026 call is available; its content is not provided in the source data.
- Q4 pivotal readout for wet AMD gene therapy (YELLOW, MARKET WIRE): Per Yahoo Finance, the company is anticipating a Q4 pivotal readout for a one-time wet AMD gene therapy. This is the key binary event named in the feed.
- Mizuho upside call on two lead gene therapies (YELLOW, MARKET WIRE): Per Yahoo Finance, Mizuho's call references nearly 200% upside tied to two lead gene therapies.
Risk watch items: leadership turnover and the outcome of the pivotal readout. Proprietary signals: none. Per the Butterfly Supply-Chain Graph, no butterfly links are recorded.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector correlations beyond the Health Care classification are not available in source data. The second-order item a prospective investor should watch is the pivotal readout named in the news feed, since a result there would be expected to reprice the stock across the sector-sensitive beta profile noted in the RQD rating.
Open Questions
- What are the outcomes and timing of the Q4 pivotal wet AMD gene therapy readout, and how would they affect the cash position of $34.5M?
- What is the company's debt balance, given that debt is listed as N/A across all reported periods?
- What drove the operating loss of $-161.2M in FY 2025 and the cash burn implied by FCF of $-126.4M?
- What is the basis for Mizuho's outperform rating and its nearly 200% upside call, given that analyst data is not provided?
- Who are the institutional and insider holders, and what are their recent position changes?
RGNX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for REGENXBIO Inc. (RGNX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Australia • 15h ago
REGENXBIO Inc. (RGNX) stock price, news, quote and history Yahoo Finance Australia report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 18h ago
Mizuho initiates Regenxbio stock coverage with outperform rating Investing.com report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 21h ago
RegenXBio Announces Board Leadership Changes After Resignation The Globe and Mail report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Full Transcript: Regenxbio Q2 2026 Earnings Call - Regenxbio (NASDAQ:RGNX) Benzinga report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy Yahoo Finance report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call Yahoo Finance report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
REGENXBIO stock: Bank of America sets USD 15.00 target for REGENXBIO stock ad-hoc-news.de report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST ad-hoc-news.de • 1d ago
REGENXBIO schedules October 20 event: REGENXBIO stock gains 8.87 percent ad-hoc-news.de report covering REGENXBIO Inc. (RGNX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RGNX Bull vs. Bear Conversation Board — What's Your Call at $7.20?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RGNX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $6.52 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is RGNX (E • RQD 27/100) a Buy at $7.41?
Welcome to the RGNX (REGENXBIO Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $5.78 (-22.0%)
Spot @ $7.41 Pump the brakes on RGNX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on RGNX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless REGENXBIO Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $8.52 (+15.0%)
Spot @ $7.41 RGNX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on RGNX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.41 (52-wk range $5.45 - $16.19), any beat on forward guidance forces shorts and underweight funds to chase.